Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
CCOP - Northern New Jersey
mi
from
Hackensack, NJ
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
CCOP - Northern New Jersey
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Beth Israel Medical Center - Petrie Division
mi
from
New York, NY
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Beth Israel Medical Center - Petrie Division
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
St. Rita's Medical Center
mi
from
Lima, OH
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
St. Rita's Medical Center
mi
from
Lima, OH
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Foote Memorial Hospital
mi
from
Jackson, MI
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Foote Memorial Hospital
mi
from
Jackson, MI
Click here to add this to my saved trials
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated:  12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features
Status: Enrolling
Updated: 12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
Arizona Cancer Center - Tucson
mi
from
Tucson, AZ
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
Arizona Cancer Center - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  12/12/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 12/12/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  12/12/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 12/12/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  12/12/2017
Northwestern University
mi
from
Chicago, IL
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 12/12/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  12/12/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 12/12/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older
Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation
Status: Enrolling
Updated:  12/12/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older
Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation
Status: Enrolling
Updated: 12/12/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older
Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation
Status: Enrolling
Updated:  12/12/2017
The West Clinic/ University of Tennesee West Cancer Center
mi
from
Memphis, TN
The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older
Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation
Status: Enrolling
Updated: 12/12/2017
The West Clinic/ University of Tennesee West Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Rush University Medical Center
mi
from
Chicago, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
St. John's Regional Health Center
mi
from
Springfield, MO
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Mount Carmel West Hospital
mi
from
Columbus, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Mount Carmel West Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Harrington Cancer Center
mi
from
Amarillo, TX
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Michiana Hematology Oncology
mi
from
Plymouth, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Michiana Hematology Oncology
mi
from
Plymouth, IN
Click here to add this to my saved trials